Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-13T00:48:16.061Z Has data issue: false hasContentIssue false
  • English
  • Français

Closing the Treatment Gap: The EPA Case Study of Schizophrenia

Published online by Cambridge University Press:  23 March 2020

W. Gaebel
W. Gaebel*
Affiliation:
Heinrich-Heine-universität Düsseldorf, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia still ranks among the first 10 leading causes of disability worldwide. Recent analyses show that there is a considerable treatment gap in schizophrenia in Europe and worldwide.

Objectives

To provide evidence-based information and give a concise overview of what is needed to overcome the treatment gap in schizophrenia.

Methods

Using a combined approach of systematic review and health economics was used to assess the socioeconomic impact of medical interventions (or the lack of thereof) for schizophrenia.

Conclusions

The case study analysis demonstrates socioeconomic impact and health gains of best practices in specific healthcare interventions for schizophrenia in comparison with the cost burden of current care or non-treatment.

Disclosure of interest

Unterstützung bei Symposien/Symposia Support

– Janssen-Cilag GmbH, Neuss

– Aristo Pharma GmbH, Berlin

– Lilly Deutschland GmbH, Bad Homburg

– Servier Deutschland GmbH, München

– Fakultätsmitglied/Faculty Member

– Lundbeck International Neuroscience Foundation (LINF), Dänemark

Type
Joint symposium: The value of treatment for brain and mental disorders
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S4
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.